Trial Profile
Safety and effectiveness of ruxolitinib as a salvage therapy in refractory graft-versus-host disease after allogenic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.